Last $20.20 USD
Change Today -0.46 / -2.23%
Volume 204.3K
RGEN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:20 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

repligen corp (RGEN) Snapshot

Open
$20.63
Previous Close
$20.66
Day High
$20.73
Day Low
$20.09
52 Week High
07/14/14 - $24.68
52 Week Low
09/5/13 - $9.41
Market Cap
659.5M
Average Volume 10 Days
385.5K
EPS TTM
$0.54
Shares Outstanding
32.6M
EX-Date
--
P/E TM
37.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for REPLIGEN CORP (RGEN)

Related News

No related news articles were found.

repligen corp (RGEN) Related Businessweek News

No Related Businessweek News Found

repligen corp (RGEN) Details

Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor products, which are used to increase cell growth and productivity during upstream fermentation. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality test kits. Further, it has a portfolio of therapeutic product candidates, which include RG3039, a small molecule drug candidate in clinical development for spinal muscular atrophy; histone deacetylase inhibitor for the treatment of Friedreich’s ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other related diseases. Additionally, Repligen Corporation offers alternating tangential flow system, a filtration device used to improve product yields during the fermentation step of the biologic drug manufacturing process. The company sells its bioprocessing products are to various life sciences companies, biopharmaceutical manufacturing companies, and contract manufacturing organizations worldwide. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

repligen corp (RGEN) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $475.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $293.0K
Vice President of Business Development
Total Annual Compensation: $262.5K
Senior Advisor
Total Annual Compensation: $272.5K
Compensation as of Fiscal Year 2013.

repligen corp (RGEN) Key Developments

Repligen Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revised Earnings Guidance for the Full Year 2014

Repligen reported consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue was $15.55 million against $17.51 million a year ago. Income from operations was $3.106 million against $6.103 million a year ago. Income before income taxes was $3.243 million against $6.033 million a year ago. Net income was $2.825 million or $0.09 diluted per share against $4.54 million or $0.14 diluted per share a year ago. For the six months, the company reported total revenue was $31.88 million against $33.965 million a year ago. Income from operations was $8.414 million against $9.65 million a year ago. Income before income taxes was $8.641 million against $9.66 million a year ago. Net income was $7.102 million or $0.22 diluted per share against $6.88 million or $0.21 diluted per share a year ago. The company raised its revenue guidance for 2014, now expecting total revenue of $59 million to $62 million, up from $58 million to $61 million provided on June 3, 2014. Total product revenue for 2014 is expected to be $57-$60 million, an increase from previous guidance of $56-$59 million. This reflects annual growth of 20%-26%. Product gross margin for the full year 2014 is expected to be 53%-55%, an increase from previous guidance of 51%-53%. Total income from operations for the full year 2014 is expected to be $11-$13 million, increased from previous guidance of $10-$12 million. Effective tax rate for 2014 is expected to be 23%-25% of pretax net income, an increase from previous guidance of 20%-22%. Total net income projection for 2014 is $8-$10 million, consistent with previous guidance. The company expects to end the year 2014 with $64-$68 million in cash and cash investments, an increase from previous guidance of $62-$66 million. Capital expenditures for the year are expected to be $6 million.

Repligen Corporation to Report Q2, 2014 Results on Aug 11, 2014

Repligen Corporation announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Aug 11, 2014

Repligen Corporation, Q2 2014 Earnings Call, Aug 11, 2014

Repligen Corporation, Q2 2014 Earnings Call, Aug 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGEN:US $20.20 USD -0.46

RGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bristol-Myers Squibb Co $50.25 USD -0.52
View Industry Companies
 

Industry Analysis

RGEN

Industry Average

Valuation RGEN Industry Range
No financial data is available for RGEN.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REPLIGEN CORP, please visit www.repligen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.